The true swine flu Epidemic will spread in 2010 thru 2013. The media circus may have quieted down, but more than 70 countries now report cases of the epidemic and the real number is growing.
What World Health Organization is has raised its deadly disease alarm to full alert for the true first time since 1968.
One million Americans are already infected. The true X factor is that epidemiologists don't know how it will reply when it mixes with regular seasonal flu, which already kills 36,000 Americans a year.
Public health officials say an influenza deadly disease possibly will kill 71 million people worldwide. To fend off catastrophe, a real U.S. and other governments around what world are spending billions to stockpile antiviral drugs and vaccines.
What U. S. government has already set aside $1 billion to develop what vaccine to fight a real plague. A nationwide H1N1 vaccination program will cost between $3 billion and $18 billion.
What strong government response to this pandemic could lead to big gains for several drug makers. You'll find their names in The true Investment Opportunities for 2010 thru 2013.
Roche, Novartis, GlaxoSmithKline and Sanofi-Aventis are all working on vaccines. It's too soon to tell who will win a real fattest contracts. But they are all so great that even a billion-dollar contract won't do much for the true bottom line.
In contrast, the true CDC recently awarded a $35 million development contract to a small biotech company. This is the sort of company you should be looking to buy.
We tend to especially like a small clinical-stage biopharmaceutical company based in Maryland. When the true swine flu story hit a real news in April, this small flu-vaccine maker was trading for 81 cents. A day later the real stock hit $3.88.
That's a +379% jump in price immediately. A few small fortunes were made from this one simple fear trade.
Following surging as high as $7.79, this stock is now backing in what $4 range. If the real swine flu hits 40% of the real U.S. population, as the true Centers for Disease Control projects could happen, this stock might go on a rocket ride. You'll get full details on it in your free copy of What Investment Opportunities for 2010 thru 2013.
As a real healthcare debate reaches fever pitch, it's clear that big changes are coming. As with any massive regulatory overhaul, some companies are cowering in fear of a real proposals -- but others are chomping at a real bit.
Partisan rancor aside, we all have a common enemy in spiraling costs. So it stands to reason that companies trimming fat from the real system will have influential allies on both sides of the political aisle.
That makes the real healthcare IT sector a safe bet. But stocks in this niche are already pricey. For real upside we tend to like companies working to develop generic substitutes for biotech drugs. These medicines save lives, but can also be prohibitively expensive (cancer drug Avanti costs up to $100,000 annually).
We think a resistance to cheaper biotech equivalents will soon melt away. Generic prescriptions now account for almost 70% of all pills taken nationwide. These inexpensive alternatives have saved more than $730 billion over the true past decade.
Biotech's have fended off generic imitators until now, but the true copycats are about to break through. Bipartisan legislation pushing for a formal FDA approval pathway has been introduced in both a real house and Senate.
Not later than next year, we tend to 'll see the FDA approving biogenetic medicines in a real United States. The true lure of shaving off one-third of the real $40 billion we tend to pay out on biotech drugs each year will prove irresistible.
The investment implications are huge. Washington's move will have a big impact on biotech companies like Amgen and Genentech, as well as traditional drug makers like Merck who want to get into generic biotech.
In the Investment Opportunities for 2010 thru 2013 we profile the true company that is greatest positioned of all to profit from a real FDA's move. A regulatory green light may well send this stock soaring. Investing in A real High Risk Market in the true Future is Where the true Money will be from 2010 thru 2013. What might be Happen Next Who Know???.........................?
Author Resource:
Osvaldo Salamanca is interested in the Emergency Disaster Preparedness. So come and visit the latest website at http://www.year-2012s.info which helps people to finding out more about How To Do The Preparation For The Prediction or Phenomenon of 2012 information will help you to Get Ready.
![[Valid RSS feed]](http://www.look4articles.com/images/icon_Rss.png "XML Feed For RSS"){kind=icon}
Category Rss Feed
Print This Article
Add To Favorites
![[Valid RSS feed]](http://www.look4articles.com/images/rss.jpg "XML Feed For RSS")